IMPA (immune-mediated polyarthritis) in dogs does have a genetic component, though it is not caused by a single inherited gene in most cases. The condition arises from a complex interaction between genetic susceptibility and environmental triggers, meaning some dogs are born with immune system traits that make them significantly more likely to develop the disease. Certain breeds face dramatically higher risks than others, and researchers have now identified specific genetic markers tied to that vulnerability.
How Genetics Influence IMPA Risk
IMPA is not inherited the way a simple trait like coat color is. Instead, it follows a complex inheritance pattern, meaning multiple genes contribute to a dog’s susceptibility rather than one gene dictating whether the disease will appear. Genome-wide association studies in breeds like the Nova Scotia Duck Tolling Retriever have pinpointed several locations in the genome that contain genes involved in immune regulation, and a particular immune system gene complex (called MHC class II) has been confirmed as a genetic risk factor for the disease in that breed.
The most detailed genetic work so far comes from research on dachshunds in Japan. Scientists examined a specific immune gene called DLA-DRB1, which is the dog equivalent of a gene strongly linked to rheumatoid arthritis in humans. They found that dachshunds carrying certain amino acid variations at three key positions on this gene had nearly three times the odds of developing IMPA compared to dachshunds without those variations. Dogs that carried two copies of one particular high-risk version of the gene were at even greater risk. This mirrors what researchers have long known about rheumatoid arthritis in people, where similar immune gene variations drive susceptibility.
Breeds With Higher IMPA Risk
Breed-associated polyarthritis syndromes have been documented in the Akita, boxer, Weimaraner, Bernese mountain dog, German shorthaired pointer, spaniel, and beagle. More recent studies have added the whippet, cocker spaniel, miniature schnauzer, Cairn terrier, Hungarian Vizsla, and German shepherd dog to the list of breeds that appear overrepresented.
The Nova Scotia Duck Tolling Retriever stands out as a particularly striking example. Insured Swedish Tollers were 18 times more likely to develop immune-mediated rheumatic disease than dogs of all other breeds combined, and 30 times more likely than other retriever breeds. Female Tollers faced an even higher risk, roughly nine times that of males within the breed. These numbers, combined with the identified heritable risk factors, make a strong case for a breed-level genetic predisposition.
The Chinese Shar-Pei represents the clearest example of a single-gene contribution to an autoinflammatory condition that includes joint inflammation. Researchers identified a specific mutation in a gene called MTBP through whole genome sequencing. Shar-Pei that carried two copies of this mutation all developed the autoinflammatory disease (known as SPAID), while those with no copies remained unaffected. Dogs with one copy had about twice the risk, suggesting an incomplete dominant inheritance pattern. This mutation promotes inflammatory reactions through a specific cellular pathway, driving the recurrent fevers and joint swelling the breed is known for.
Genetics Alone Don’t Tell the Whole Story
Even in high-risk breeds, not every dog develops IMPA. The condition is classified into different types based on what triggers the immune system to attack the joints. Type I, the most common form, is considered idiopathic, meaning no specific external cause is found. Types II through IV are associated with identifiable triggers like infections elsewhere in the body, gastrointestinal disease, or cancers. In all cases, the immune system produces antibody complexes that deposit in the joint lining, causing inflammation, pain, and swelling in multiple joints simultaneously.
Environmental factors clearly play a role in tipping a genetically susceptible dog into active disease. Infections, vaccinations, certain medications, and other immune challenges have all been associated with IMPA onset. Think of it as a threshold: genetics load the gun, and environmental factors pull the trigger. A dog with high-risk immune gene variants may go its entire life without developing IMPA if it never encounters the right combination of triggers, while another dog with the same genetic profile might develop the condition after a routine infection.
What This Means for Breeding and Testing
Because IMPA involves multiple genes and complex inheritance, there is no single genetic test available for most breeds that can definitively predict whether a dog will develop the condition. The Shar-Pei is the exception, where the identified MTBP mutation allows for more targeted screening. For other breeds, the genetic picture remains incomplete, though the identified DLA-DRB1 associations in dachshunds and MHC class II haplotype risks in Tollers represent meaningful steps toward breed-specific genetic testing.
If you own or breed a dog from a high-risk breed, awareness matters more than anxiety. IMPA typically shows up as shifting leg lameness, stiffness (especially after rest), reluctance to move, fever, and lethargy. The signs can be subtle early on, sometimes resembling general stiffness or a dog that just seems “off.” Diagnosis requires sampling fluid from multiple joints to check for the characteristic inflammatory cell counts that confirm immune-driven joint inflammation. Early detection and treatment with immunosuppressive therapy generally leads to better outcomes, with many dogs achieving remission.
For breeders working with predisposed breeds, tracking which lines produce affected dogs can help inform mating decisions even without a formal genetic test. The complex inheritance pattern means eliminating IMPA from a breed entirely through selection is difficult, but reducing the frequency of high-risk gene combinations is a realistic goal when health data is shared openly within breeding communities.